La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Anhui Huaheng Biotechnology Crescita futura

Future criteri di controllo 6/6

Anhui Huaheng Biotechnology prevede che gli utili e i ricavi cresceranno rispettivamente di 26.5% e 29.5% all'anno. Si prevede che l'EPS crescerà di 26.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 27.5% in 3 anni.

Informazioni chiave

33.0%

Tasso di crescita degli utili

29.3%

Tasso di crescita dell'EPS

Chemicals crescita degli utili	30.7%
Tasso di crescita dei ricavi	32.0%
Rendimento futuro del capitale proprio	28.1%
Copertura analitica	Good
Ultimo aggiornamento	15 Aug 2024

Aggiornamenti recenti sulla crescita futura

Earnings Report: Anhui Huaheng Biotechnology Co., Ltd. Missed Revenue Estimates By 37%

Apr 23

Recent updates

Many Would Be Envious Of Anhui Huaheng Biotechnology's (SHSE:688639) Excellent Returns On Capital

Aug 20

Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jul 22

Anhui Huaheng Biotechnology Co., Ltd.'s (SHSE:688639) Intrinsic Value Is Potentially 43% Above Its Share Price

Jul 12

Is Anhui Huaheng Biotechnology (SHSE:688639) Using Too Much Debt?

Jun 21

Take Care Before Jumping Onto Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Even Though It's 27% Cheaper

Jun 05

We Ran A Stock Scan For Earnings Growth And Anhui Huaheng Biotechnology (SHSE:688639) Passed With Ease

May 12

Earnings Report: Anhui Huaheng Biotechnology Co., Ltd. Missed Revenue Estimates By 37%

Apr 23

Anhui Huaheng Biotechnology Co., Ltd.'s (SHSE:688639) Business Is Trailing The Market But Its Shares Aren't

Mar 18

Previsioni di crescita degli utili e dei ricavi

SHSE:688639 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	5,162	1,037	558	1,012	6
12/31/2025	4,024	826	403	1,025	7
12/31/2024	3,167	633	-256	450	7
6/30/2024	2,105	408	-1,102	125	N/A
12/31/2023	1,938	449	-968	301	N/A
9/30/2023	1,799	423	-664	480	N/A
6/30/2023	1,640	382	-328	451	N/A
3/31/2023	1,548	346	-200	381	N/A
12/31/2022	1,419	320	-99	357	N/A
9/30/2022	1,317	283	8	263	N/A
6/30/2022	1,203	235	-54	151	N/A
3/31/2022	1,059	192	-43	170	N/A
12/31/2021	954	168	-85	96	N/A
9/30/2021	748	138	-76	111	N/A
6/30/2021	608	118	-4	161	N/A
3/31/2021	523	120	8	74	N/A
12/31/2020	487	121	37	110	N/A
12/31/2019	491	126	100	181	N/A
12/31/2018	421	76	26	89	N/A
12/31/2017	383	65	N/A	106	N/A
6/30/2017	367	72	N/A	111	N/A
3/31/2017	339	67	N/A	83	N/A
12/31/2016	311	62	N/A	55	N/A
9/30/2016	282	51	N/A	41	N/A
6/30/2016	253	40	N/A	26	N/A
3/31/2016	253	41	N/A	31	N/A
12/31/2015	253	43	N/A	35	N/A
9/30/2015	249	34	N/A	28	N/A
6/30/2015	244	41	N/A	35	N/A
3/31/2015	235	40	N/A	39	N/A
12/31/2014	225	23	N/A	31	N/A
9/30/2014	216	27	N/A	33	N/A
6/30/2014	207	30	N/A	35	N/A
3/31/2014	190	22	N/A	38	N/A
12/31/2013	173	13	N/A	41	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 688639 ( 26.5% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 688639 ( 26.5% all'anno) cresceranno più rapidamente del mercato CN ( 21.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 688639 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 688639 ( 29.5% all'anno) crescerà più rapidamente del mercato CN ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 688639 ( 29.5% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 688639 sarà elevato tra 3 anni ( 27.5 %)

Anhui Huaheng Biotechnology Crescita futura

Future criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 12% to CN¥104

Earnings Report: Anhui Huaheng Biotechnology Co., Ltd. Missed Revenue Estimates By 37%

Price target increased by 13% to CN¥146

Price target increased to CN¥184

Price target increased to CN¥165

Price target increased to CN¥110

Recent updates

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Many Would Be Envious Of Anhui Huaheng Biotechnology's (SHSE:688639) Excellent Returns On Capital

Price target increased by 12% to CN¥104

Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Anhui Huaheng Biotechnology Co., Ltd.'s (SHSE:688639) Intrinsic Value Is Potentially 43% Above Its Share Price

Now 23% undervalued after recent price drop

Anhui Huaheng Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Is Anhui Huaheng Biotechnology (SHSE:688639) Using Too Much Debt?

Take Care Before Jumping Onto Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Even Though It's 27% Cheaper

Anhui Huaheng Biotechnology Co., Ltd., Annual General Meeting, Jun 25, 2024

We Ran A Stock Scan For Earnings Growth And Anhui Huaheng Biotechnology (SHSE:688639) Passed With Ease

Earnings Report: Anhui Huaheng Biotechnology Co., Ltd. Missed Revenue Estimates By 37%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Anhui Huaheng Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024

Anhui Huaheng Biotechnology Co., Ltd.'s (SHSE:688639) Business Is Trailing The Market But Its Shares Aren't

Now 22% overvalued after recent price rise

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improves as stock rises 19%

Now 31% overvalued after recent price rise

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Anhui Huaheng Biotechnology Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment deteriorates as stock falls 21%

Price target increased by 13% to CN¥146

First quarter 2023 earnings released: EPS: CN¥0.75 (vs CN¥0.51 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥2.94 (vs CN¥1.70 in FY 2021)

Price target increased to CN¥184

Anhui Huaheng Biotechnology Co., Ltd. announced a financing transaction

Price target increased to CN¥165

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥0.37 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.68 (vs CN¥0.32 in 2Q 2021)

Price target increased to CN¥110

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.35 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita